Artgen Biotech Group expects to increase its revenue to at least ₽10 billion by 2030. Multiple revenue growth will ensure both the launch of new drugs and the expansion of indications for existing drugs. In 9M 2023, the company reported revenue of ₽963.98 million, up 17.9% from ₽817.89 million a year earlier. In 2022, revenue fell 3.7% to ₽1.137 billion compared to ₽1.181 billion a year earlier.